Randomized Phase III Study of Exemestane (Aromasin) for 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed by Exemestane - Contacts and Locations

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Randomized Phase III Study of Exemestane (Aromasin) for 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed by Exemestane

This study is ongoing, but not recruiting participants.

Study NCT00036270. Last updated on November 22, 2008. Information provided by Pfizer

Please refer to this study by its ClinicalTrials.gov identifier: NCT00036270

Locations


United States, Texas
	Pfizer Investigational Site
	Dallas, Texas, United States, 75204

Sponsors and Collaborators

Pfizer

Investigators


Study Director:	Pfizer CT.gov Call Center	Pfizer